Cocrystal Pharma Files 8-K with Financials & Reg FD

Ticker: COCP · Form: 8-K · Filed: Dec 31, 2024 · CIK: 1412486

Sentiment: neutral

Topics: financial-statements, regulation-fd, corporate-update

TL;DR

Cocrystal Pharma dropped its 8-K on Dec 31st - check financials & Reg FD!

AI Summary

Cocrystal Pharma, Inc. filed an 8-K on December 31, 2024, reporting on its financial statements and exhibits. The filing also includes a Regulation FD Disclosure. The company, formerly known as BIOZONE PHARMACEUTICALS, INC. and International Surf Resorts, Inc., is incorporated in Delaware and headquartered in Bothell, WA.

Why It Matters

This filing provides an update on Cocrystal Pharma's financial status and regulatory disclosures, which are important for investors to assess the company's performance and compliance.

Risk Assessment

Risk Level: low — This is a routine filing of financial statements and exhibits, not indicating any immediate operational or financial distress.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on financial statements and exhibits, as well as to provide a Regulation FD Disclosure.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on December 31, 2024.

What are the former names of Cocrystal Pharma, Inc.?

Cocrystal Pharma, Inc. was formerly known as BIOZONE PHARMACEUTICALS, INC. and International Surf Resorts, Inc.

In which state is Cocrystal Pharma, Inc. incorporated?

Cocrystal Pharma, Inc. is incorporated in Delaware.

What is the principal executive office address for Cocrystal Pharma, Inc.?

The principal executive office address for Cocrystal Pharma, Inc. is 19805 N. Creek Parkway, Bothell, WA 98011.

Filing Stats: 440 words · 2 min read · ~1 pages · Grade level 10.7 · Accepted 2024-12-31 08:30:12

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 31, 2024 Cocrystal Pharma, Inc. By: /s/ James Martin Name: James Martin Title: Chief Financial Officer and Co-Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing